

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Health Technology Evaluation

### Equality impact assessment – Scoping

#### Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer ID4004

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Several equality considerations were highlighted:

- Prostate cancer disproportionately affects men of black ethnicity
- Greater representation of men from ethnic minority backgrounds (including men of black ethnicity) is needed to find out if study results are generalisable
- The olaparib plus abiraterone combination includes prednisolone (steroid) as one of the treatment components. This was said to pose the risk of steroid exposure which is difficult for a set of the population.
- Abiraterone was said to not be the first-choice option of newer hormonal treatment for some people. So, a combination containing a different newer hormonal treatment (enzalutamide) and without prednisolone was said to promote equality and ensure all eligible patients have access to a PARPi combination.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

According to NICE's [manual](#) and [principles](#), the committee will consider whether its recommendations could have a different impact on people protected by the equality legislation than on the wider population.

The initial view is that it will not be an equalities issue. This is because:

- Differences in the incidence and prevalence cannot be addressed in a technology appraisal.
- If recommended as a treatment option, the choice of treatment is made between a patient and their healthcare professional based both on evidence and on the person's individual preferences, beliefs and values. All recommended treatment options can be considered.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

Yes, the Caribbean and African Health Network were identified as an additional stakeholder and were added to the stakeholder list.

**Approved by Associate Director (name):** ...Richard Diaz.....

**Date:** 15 July 2024